Search Results

Anixa Biosciences, Inc. today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial.

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Anixa Biosciences, Inc., a clinical-stage biotechnology company focused on the treatment and prevention of cancer, announced that it has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types.

Anixa Biosciences, Inc. today announced its participation in the Sidoti Micro-Cap Virtual Conference, taking place May 8-9, 2024.

Anixa Biosciences, Inc today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board.

Anixa Biosciences, Inc. today announced that Dr. Amit Kumar , Chairman and CEO of Anixa, will participate in the 24th Annual World Vaccine Congress being held April 1-4, 2024.

Anixa Biosciences, Inc. today announced that it will host its 2024 Annual Meeting of Stockholders (the “Meeting”) on Thursday, March 21, 2024 at 10:00 a.m. Pacific Time in a virtual format.